All In Biotech

Drug Trial Radar · NCT05345197

Emicizumab in Patients With Acquired Hemophilia A

Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial

Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Aug 31, 2022

Primary completion

Jul 2026

Study completion Dec 2026

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Genentech, Inc.
First posted
Apr 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

Conditions

  • Acquired Hemophilia A

Interventions

  • emicizumabDrug

    This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome MeassureTime frame: 12 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • UCSD Hemophilia and Thrombosis Treatment Center

    San Diego, California

  • Georgetown University

    Washington D.C., District of Columbia

  • Emory University

    Atlanta, Georgia

  • Bleeding and Clotting Disorders Institute

    Peoria, Illinois

  • Indiana Hemophilia and Thrombosis Center, Inc.

    Indianapolis, Indiana

  • Tulane University

    New Orleans, Louisiana

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • University of North Carolina

    Chapel Hill, North Carolina

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Penn Blood Disorders Program, Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Hemophilia Center of Western Pennsylvania

    Pittsburgh, Pennsylvania

  • University of Vermont Medical Center

    Burlington, Vermont

  • UVA Comprehensive Cancer Center

    Charlottesville, Virginia

  • Washington Center for Bleeding Disorders

    Seattle, Washington

  • Versiti Inc.

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.